From China to the US, we keep working to make the world a healthier place.
Dr. James Dewey Watson, world-renowned molecular biology scientist, geneticist, and one of the leaders of molecular biology in the 20th century. In 1953, he and Francis Crick discovered the double helixstructure of DNA (including the central dogma). In 1962, Watson shared the Nobel Prize in Physiology or Medicine with Crick and Maurice Wilkins.
The discovery of the double helix structure of DNA is one of the most important scientific discoveries in the 20th century, an important milestone in the history of science. Together with natural selection, it unifies the concept of biology and marks the birth of molecular genetics. Watson, who was only 25 years old at the time, became a celebrity scientist.
Dr. Watson also played an important leading role in the Human Genome Project, the Moon Shot Project of life sciences, which was completed at the beginning of the 21st century after more than a decade’s hard work. For the first time in human history, we obtained our own “Book of Life”.
From 1968 to 2007, Watson served as the director/chancellor of Cold Spring Harbor Laboratory, leading it to become one of the best research centers in the world. In 2012, Watson was named one of the 20 Most Influential Figures in American History by Time Magazine. In 2012, Watson was named one of the 20 Most Influential Figures in American History by Time Magazine
At the advanced age of over 90, Dr. Watson’s last wish in life is to fight and win the War On Cancer. To this day, he still keeps on reading and thinking, and studies new therapeutic technologies diligently. In collaboration with Cheerland, Dr. Watson hopes to bring affordable cancer drugs to the people of China and the world.
Founder of Cheerland Investment Group and Cheerland Biomedicine, Mr. Liu has over 20 years of experiences in capital investment and business operations in China and abroad. He has established several successful companies in various industries in China and the US, and has successfully led many cross-border and cross-market transformations of the companies he founded. He has a Master’s degree in Business Operations from Nanyang Technological University, Singapore.
Renowned financier and entrepreneur, Dr. Ma is currently the chairman of the board of directors of the Shenzhen International Public Welfare Institute, the executive director of the Chinese Finance Society, and the executive director of the Chinese Business Leaders’ Association. Former President of China Merchants Bank; Chairman of the National Science and Technology Achievement Transformation Guidance Fund, and other important positions. On Fortune’s “2012 China’s 50 Most Influential Business Leaders” list, Dr. Ma ranked 35th. He holds a Ph.D. in Economics from Southwestern University of Finance and Economics, and an Honorary Doctorate degree from the University of Southern California.
With 25 years of experiences in international biotech & CDMO, Mr. Garvey held various executive, technical, and operational leadership positions in biopharmaceutical companies in the U.S., Asia, and Europe. He served as Global Head of Technical Operations, BeiGene; a founding Executive member and Vice President of Samsung Biologics Manufacturing, where he helped design, validate, technology transfer, operate, and successfully licensed an impressive +14 novel medicines in the largest Drug Substance facility (362,000L of capacity) in a single location; and various technical and management positions at global pharmaceutical companies such as Takeda, Sanofi and Genentech.
Managing over a billion dollars of AUM for Cheerland’s overseas investment arm based in New York City, Ms. Liu led/participated in dozens of investment deals in both real estate and biotech in the past several years. She holds M.S. and B.S. degrees in Business Management from the University of Edinburgh, UK.
Dr. Su has over 30 years’ experiences in biotech and pharmaceutical industry in US, Europe and Asia. He was involved with multiple IND and BLA submissions and building several cGMP facilities in the US and China. He has served at executive positions in biotech start-ups as well as multi-national pharma companies: CEO of Yuanda Biotech; SVP and COO of Henlius Biotherapeutics; EVP and CSO of GenSci Pharmaceuticals; EVP and COO of Sorrento Therapeutics; CSO of Cytovance Biologics. Other companies Dr. Su has worked for included Human Genome Sciences, Medarex, Tanox, CancerVax, The Dow Chemical Company, and Sanofi-Pasteur. Dr. Su got his B.S. in Chemistry from Nankai University; Ph.D. in Biochemistry from Carleton University, Ottawa, Canada. He has authored 26 papers in peer reviewed journals (including Science) and is also an inventor of 21 approved patents and patent applications.
Professor of Liaocheng University, Dr. Zhengping Wang graduated from Ghent University, Belgium. She also studied for her MBA at Business School, Louisiana State University, USA. She worked for two years in Chinese Academy of Sciences and eight years at LSU, doing both research and teaching. From 1997 to 2005, she worked as a senior executive in a Fortune 500 German company, and CEO of a large anti-viral API enterprise from 2005 to 2012. After that, she accepted the invitation of Shandong Liaocheng University, and assisted the university to establish its pharmaceutical college and played a leading role in establishing and operating the platform combining teaching, research and production.
A Collaborative Regulatory Affairs and Quality leader with over 20 years of broad expertise in biologics development and large-scale, global manufacturing, Dr. Fernandez served as Senior Director of Global Regulatory Affairs, Samsung Biologics; Associate Director of Global Regulatory Affairs, Shire / Baxalta / Baxter Healthcare. He holds a Ph.D. in analytical chemistry from University of California.
With extensive biotech commercialization experiences, Mr. Li served as Deputy Director of the National Engineering Research Center, as well as executives positions at Roche and Baiyunshan Pharmaceutical. At Roche, he developed the first standard unit for molecular testing of hepatitis C, and the world’s first fully automatic instrument for quantitative diagnosis of viruses, which has contributed to developing new diagnostic methods for AIDS and hepatitis C. He holds an MS from Sun Yat-sen University, and MBA from Michigan University.
Managing multiple biologics manufacturing factories, Mr. Li previously served as CEO of Peking University Biopharmaceutical; SVP of Shanghai Powerway Biomedical; Project Director of BeiGene Guangzhou; Factory Director of Wuhan Xikang Biomedical; Deputy General Manager of German Roman Group; Deputy GM of Chengdu Dirui Pharmaceutical; Deputy GM of Shanghai BioMab. He also held executive positions at GSK, Roche and Boehringer Ingelheim.
With global regulatory experience for different product lines, such as vaccines, blood products, small molecules and biological drugs, Dr. Zhang served as independent consultant to Samsung Biologics; Deputy Director, Biomarin International Regulatory Agency; Global Regulatory Affairs Manager, Baxter; Regulatory Affairs Manager, Pfizer; Regulatory Scientist, Medtronic; Research Scientist, CancerVax. She holds a Ph.D. from North Carolina State University; Master of Law in Regulatory Affairs from San Diego State University.
Dr. Richard Zhu has 20+ years of experience in pharmaceutical industry. He graduated from Peking University and obtained his PhD in organic chemistry in Canada. After postdoc training in medicinal chemistry in USA, he joined Jansen Pharmaceuticals as a senior scientist. He previously served as a patent specialist at Eckert Seamans Cherin & Mellott LLC and VP of medicinal chemistry at Fujian Jinler Pharmaceuticals. Dr. Zhu has extensive experience in the research and development of new drugs for metabolic diseases and oncology. He is the main inventor of the FDA approved oncology drug AZEDRA.
Dr. Li got her Ph.D in Biomedical Engineering from City University of New York and has published 15 peer-reviewed papers. She has rich experience in research and development of antibody drugs and cell therapeutics. Her career experience includes pre-clinical drug development in Wuxi AppTec and cell therapy product development in BGI.
Currently Chairman and Chief Scientist of Jiangsu Antai Biotechnology, he was a professor at the Fourth Military Medical University; Director of the Reproductive Health Quality Control Center of the National Family Planning Commission; Executive Vice Chairman of the China Reproductive Health Products Standardization Committee; Director of Therapeutic Cell Vaccine Engineering Research Center, Jiangsu Province. He was one of the pioneers in China in the research and development and industrialization of gene diagnosis, biochip and cell targeted therapy technology. Authored 22 patens and published more than 300 papers, as well as 6 books.
Dr. Zhou is currently Professor in medical cell biology at Shenzhen University. He has published over 60 papers in the areas of stem cells, disease mechanisms and regeneration of musculoskeletal and nervous systems. He also serves as an executive member of several national academic societies in musculoskeletal diseases and anti-aging research. His work has been supported by major national and international funding agencies including NSFC, MOST, Scoliosis Research Society, and Research Grant Council Hong Kong. Dr. Zhou is also a co-founder for several biotech start-ups developing advanced innovative therapy and medicine products and services.
CLBiomed just moved into its new headquarter in the first building of the still under-construction Cheerland Watson Center for Life Sciences and Technology, in May 2020. Sitting between priceless ocean view and rolling green hills, it awaits the next breakthrough in biomedicine.
2020: New Milestone, New Journey
The Cheerland Watson Center upon completion
Officially opened on May 18, 2020
Cheerland Team Building
The Next-generation of Cheerlander